PL2850075T3 - Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c - Google Patents
Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu cInfo
- Publication number
- PL2850075T3 PL2850075T3 PL13720201T PL13720201T PL2850075T3 PL 2850075 T3 PL2850075 T3 PL 2850075T3 PL 13720201 T PL13720201 T PL 13720201T PL 13720201 T PL13720201 T PL 13720201T PL 2850075 T3 PL2850075 T3 PL 2850075T3
- Authority
- PL
- Poland
- Prior art keywords
- hepatitis
- piperazine
- piperidine compounds
- virus inhibitors
- virus
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- LMRCKXYHPYNEJV-UHFFFAOYSA-N piperazine;piperidine Chemical class C1CCNCC1.C1CNCCN1 LMRCKXYHPYNEJV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637959P | 2012-04-25 | 2012-04-25 | |
| US201361774033P | 2013-03-07 | 2013-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2850075T3 true PL2850075T3 (pl) | 2017-08-31 |
Family
ID=48237291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13720201T PL2850075T3 (pl) | 2012-04-25 | 2013-04-24 | Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9206159B2 (pl) |
| EP (1) | EP2850075B1 (pl) |
| JP (1) | JP6069491B2 (pl) |
| CN (1) | CN104302639B (pl) |
| CA (1) | CA2869640C (pl) |
| CY (1) | CY1118920T1 (pl) |
| DK (1) | DK2850075T3 (pl) |
| ES (1) | ES2624846T3 (pl) |
| HR (1) | HRP20170471T1 (pl) |
| HU (1) | HUE032173T2 (pl) |
| LT (1) | LT2850075T (pl) |
| ME (1) | ME02682B (pl) |
| PL (1) | PL2850075T3 (pl) |
| PT (1) | PT2850075T (pl) |
| RS (1) | RS55864B1 (pl) |
| SI (1) | SI2850075T1 (pl) |
| WO (1) | WO2013163262A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108794454B (zh) * | 2017-04-27 | 2023-08-15 | 广东东阳光药业股份有限公司 | 一种咪唑环化合物的制备方法 |
| CN112409336B (zh) * | 2017-11-27 | 2021-09-14 | 常州寅盛药业有限公司 | 适于工业化生产的达卡他韦起始原料的合成方法 |
| WO2025036285A1 (zh) | 2023-08-11 | 2025-02-20 | 深圳众格生物科技有限公司 | 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007115805A2 (en) * | 2006-04-05 | 2007-10-18 | European Molecular Biology Laboratory (Embl) | Aurora kinase inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20120040977A1 (en) | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| UY32462A (es) | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2857394A1 (en) | 2009-05-13 | 2015-04-08 | Gilead Pharmasset LLC | Antiviral compounds |
| US8344155B2 (en) | 2009-09-04 | 2013-01-01 | Glaxosmith Kline Llc | Chemical compounds |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011031934A1 (en) * | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011081918A1 (en) | 2009-12-14 | 2011-07-07 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102883718A (zh) | 2009-12-24 | 2013-01-16 | 顶点制药公司 | 用于治疗或预防黄病毒感染的类似物 |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| JP2013522202A (ja) | 2010-03-09 | 2013-06-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合三環式シリル化合物およびウイルス疾患の治療のためのその使用方法 |
| EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| JP5891235B2 (ja) * | 2010-11-04 | 2016-03-22 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｃ型肝炎ウイルスの新規阻害剤 |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9212168B2 (en) | 2011-11-03 | 2015-12-15 | Theravance Biopharma R&D Ip, Llc | Hepatitis C virus inhibitors |
| ES2599665T3 (es) * | 2012-04-25 | 2017-02-02 | Theravance Biopharma R&D Ip, Llc | Inhibidores del virus de la hepatitis C |
-
2013
- 2013-04-24 HU HUE13720201A patent/HUE032173T2/en unknown
- 2013-04-24 US US13/869,199 patent/US9206159B2/en not_active Expired - Fee Related
- 2013-04-24 WO PCT/US2013/037920 patent/WO2013163262A1/en not_active Ceased
- 2013-04-24 RS RS20170354A patent/RS55864B1/sr unknown
- 2013-04-24 EP EP13720201.6A patent/EP2850075B1/en active Active
- 2013-04-24 CA CA2869640A patent/CA2869640C/en not_active Expired - Fee Related
- 2013-04-24 PL PL13720201T patent/PL2850075T3/pl unknown
- 2013-04-24 CN CN201380021717.8A patent/CN104302639B/zh not_active Expired - Fee Related
- 2013-04-24 PT PT137202016T patent/PT2850075T/pt unknown
- 2013-04-24 JP JP2015509099A patent/JP6069491B2/ja not_active Expired - Fee Related
- 2013-04-24 HR HRP20170471TT patent/HRP20170471T1/hr unknown
- 2013-04-24 DK DK13720201.6T patent/DK2850075T3/en active
- 2013-04-24 LT LTEP13720201.6T patent/LT2850075T/lt unknown
- 2013-04-24 ME MEP-2017-85A patent/ME02682B/me unknown
- 2013-04-24 ES ES13720201.6T patent/ES2624846T3/es active Active
- 2013-04-24 SI SI201330640A patent/SI2850075T1/sl unknown
-
2017
- 2017-05-17 CY CY20171100520T patent/CY1118920T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ME02682B (me) | 2017-06-20 |
| US20130287730A1 (en) | 2013-10-31 |
| EP2850075B1 (en) | 2017-02-22 |
| CA2869640C (en) | 2018-03-20 |
| HRP20170471T1 (hr) | 2017-06-02 |
| CY1118920T1 (el) | 2018-01-10 |
| JP2015514807A (ja) | 2015-05-21 |
| CN104302639A (zh) | 2015-01-21 |
| HUE032173T2 (en) | 2017-09-28 |
| DK2850075T3 (en) | 2017-05-22 |
| SI2850075T1 (sl) | 2017-06-30 |
| RS55864B1 (sr) | 2017-08-31 |
| WO2013163262A1 (en) | 2013-10-31 |
| EP2850075A1 (en) | 2015-03-25 |
| JP6069491B2 (ja) | 2017-02-01 |
| PT2850075T (pt) | 2017-05-02 |
| CN104302639B (zh) | 2017-03-29 |
| LT2850075T (lt) | 2017-05-10 |
| CA2869640A1 (en) | 2013-10-31 |
| US9206159B2 (en) | 2015-12-08 |
| ES2624846T3 (es) | 2017-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269662A (en) | Hepatitis C virus inhibitors | |
| IL221033A0 (en) | Hepatitis c virus inhibitors | |
| EP2575819A4 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
| ZA201306720B (en) | Hepatitis c virus inhibitors | |
| IL229270B (en) | Hepatitis c virus inhibitors | |
| IL224298A (en) | Hepatitis virus inhibitors c | |
| EP2768517A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| EP2603080A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| ZA201309356B (en) | Hepatitis c virus inhibitors | |
| PL2897611T3 (pl) | Sposób leczenia wirusowego zapalenia wątroby typu C | |
| ZA201503458B (en) | Hepatitis c virus inhibitors | |
| ZA201308011B (en) | Processes for preparing inhibitors of the hepatitis c virus | |
| PL2850075T3 (pl) | Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c | |
| EP2748160A4 (en) | INHIBITORY COMPOUNDS OF HEPATITIS C | |
| HK1192541A (en) | Hepatitis c virus inhibitors | |
| HK1192882A (en) | Hepatitis c virus inhibitors |